Insider filing · AVTX
Mittie Doyle
Chief Medical Officer
profile →
Avalo Therapeutics, Inc.
AVTX · Healthcare · 11 filings in 24 months
ticker →
Mittie Doyle sold $2.1M of Avalo Therapeutics (AVTX)
Executed May 6, disclosed May 7, 1 day later.
Value, as filed
$2.1M
101,555 sh across 4 lots
Executed
May 6
the trade date, as filed
Disclosed
May 7
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
MDMittie Doyle (Chief Medical Officer) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Avalo Therapeutics, Inc. (AVTX). The largest single filing was $2.1M of AVTX (101,555 sh across 4 lots, as filed), executed May 6.
The name
AVTXHealthcare · Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Mittie Doyle in AVTX
AVTXSALE
Avalo Therapeutics, Inc.
$412K25,492 sh × $16.15
Exec Mar 16
Filed Mar 18 · 5:30 PM ET